Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibrosis and severe ...
Hosted on MSN2mon
FDA accepts Sobi North America’s thrombocytopenia therapy sNDASobi’s sNDA is supported by data from the AVA ... Avatrombopag, known under the brand name DOPTELET, is a thrombopoietin receptor agonist (TPO-RA) that does not compete with thrombopoietin ...
Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments. As part of the deal, first announced in August ...
Swedish Orphan Biovitrum AB (publ) (Sobi), an international specialty health-care company, aims to be recognized as a global leader in providing access to innovative treatments that transform the ...
Sobi's acquired immunology drugs (Astra's Synagis ... New products like long-acting hemophilia drug Altuviiio and Altuvoct (branded names in US and Europe, respectively), myelofibrosis drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback